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Inflammation, arteriosclerosis, and cardiovascular therapy in patients have shown that attenuation of arterial stiffness
hemodialysis patients. is associated with the regression of LVH, and had a
Background. Aortic stiffness and left ventricular hypertro- favorable effect on all-cause and cardiovascular survivalphy (LVH) are predictors of mortality in hemodialysis (HD)
[6, 7]. This favorable effect was observed in less thanpatients. Attenuation of arterial stiffness and regression of
50% of patients [6, 7], and the aim of the present studyLVH had a favorable effect on survival in these patients, but
this favorable effect was observed in less than 50% of patients, was to determine the factors associated with the resis-
the rest being resistant to therapeutical interventions. The aim tance to treatment.
of this study was to analyze the factors associated with this
resistance to treatment.
Methods. 138 patients on HD were studied during a follow- METHODS
up survey. From entry until the end of follow up, the changes
Patientsof aortic pulse wave velocity (PWV) and of LV mass were
measured in response to treatment with antihypertensive drugs Criteria for inclusion into the study were HD for at
and erythropoietin, together with measurements of blood least 3 months, predialysis BP 160/90 mm Hg, goodchemistry, including high-sensitive C-reactive protein (CRP).
quality echocardiography, follow-up of at least ninePatients with decreased aortic PWV were considered to be
months, agreement to participate in the study, which wasresponders (N  68), the others to be nonresponders (N 70).
Results. Nonresponders were older (P  0.05) and had per- approved by our Institutional Review Board, and regular
sistently higher systolic blood pressure (BP) and pulse pressure. determination of blood chemistry, including CRP. One-
Responders were treated more frequently with an ACE inhibi-
hundred thirty-eight patients were included. All patientstor (P  0.001), and had lower serum CRP (P  0.01). The
were dialyzed using synthetic membranes, bicarbonatebaseline PWV, as well as the changes of PWV and LV mass
during the follow-up were significantly and independently cor- dialysate, and highly purified water treated by double
related with serum CRP level (P 0.001). According to logistic osmosis. Serum albumin, blood lipids, parathyroid hor-
regression after adjustment for age, gender, diabetes, history mone (PTH), and CRP were measured every three months
of CVD, and the nonspecific cardiovascular risk factors, the
and the last three values were averaged. Only values ofimprovement of aortic stiffness and LV hypertrophy was posi-
CRP not associated with an acute intercurrent clinicaltively associated with prescription of ACE inhibitor (P 
0.0001), and negatively with the serum CRP level (P  0.01). event were taken into consideration.
Conclusion. These results indicate that in HD patients, the
presence of low-grade inflammation decreases the efficiency Data collection
of cardiovascular therapeutic interventions and participates in
The baseline measurements were made during the twothe persistence of cardiovascular hemodynamic overload.
weeks following inclusion into the study. BP was mea-
sured with a mercury sphygmomanometer and a cuff of
appropriate size after 15 minutes of recumbency (PhasesCardiovascular disease (CVD) is the leading cause of
I and phase V of the Korotkoff sounds were taken asmortality among patients with end-stage renal disease
the systolic [SBP], and diastolic BP [DBP], respectively).(ESRD) [1]. Left ventricular hypertrophy (LVH) and
The mean BP (MBP) was calculated as: MBP  DBP arterial disease are the principal risk factors [2–4]. Arte-
[(SBP-DBP)/3], where SBP-DBP Pulse Pressure (PP).rial stiffness is a determinant of the LV pressure load and
Echocardiographic measurements were done using aof the coronary perfusion [5]. Recent studies in ESRD
Hewlett-Packard Sonos 100 equipped with a 2.25-MHz
probe (Hewlett-Packard, Evry, France), at regular inter-
Key words: dialysis, arteriosclerosis, cardiac hypertrophy, inflammation. vals (9, 18, 24 months, and then yearly). The measure-
ments of LV mass were made according to the Penn 2003 by the International Society of Nephrology
S-88
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Table 1. Characteristics of the two populationsConvention [8], and included the LV end-diastolic diam-
eter, LV posterior wall thickness (PWTH), and interven- Parameters Responders Nonresponders
tricular septal thickness (IVTh). Mean wall thickness Age years 48.214.4 53.217a
Gender male/female 41/27 37/33(MWTh) was calculated as (PWTh  IVTh)/2. Stroke
Vintage months 5355 8570bvolume (SV mL) was calculated as the aortic annular
Follow-up months 5736 5232
cross-sectional area multiplied by the velocity integral Diabetes % 5 5
History of CVD % 26 75cof LV outflow, and cardiac output as SV multiplied by
Smoking pack-years 6.210.3 13.621cheart rate and referred to as cardiac index (CI) to body
Erythropoietin yes/no 48/20 43/27
surface area. Total peripheral resistance (TPR) was com- Erythropoietin dose units/week 7041 8947a
Antihypertensive therapyputed from CI and MBP as: TPR  MBP  80/CI, and
Ultrafiltration alone % 19 31diastolic filling of the LV as E/A ratio of transmitral
Perindopril % 53 18c
velocities. Atenolol % 49 31a
Nitrendipine % 56 54Aortic stiffness was determined as aortic pulse wave
Number of antihypertensive drugs 1.61 11cvelocity (PWV) by the foot-to-foot method, using Dopp-
Body weight kg 63.114 61.513
ler flow-velocity recordings carried out simultaneously Interdialytic weight changes kg 2.542.1 2.652.2
over the common carotid artery and the femoral artery aP  0.05
bP  0.01in the groin with a 8-MHz Doppler unit (Socie´te d’Elec-
cP  0.001tronique Ge´ne´rale et Applique´e, Paris, France), as pre-
viously detailed [9].
Interventions
yes), atenolol (0  no; 1  yes) were used as dummy
The treatments and their targets were those previously variables. Multiple regression was used to test the associ-
detailed [6, 7]. The pressure overload in ESRD (high ation of variables related to changes of aortic PWV and
SBP and PP) was due principally to arterial stiffening. LV mass using the least-squares method. Logistic regres-
As arterial stiffness is normally BP-dependent, the first sions were used to analyze the variables associated with
target of the treatment was to decrease BP and to main- therapeutic responsivness (0  responders, 1  nonre-
tain predialysis BP 160/90 mm Hg, and to avoid hypo- sponders). Analyses were performed using NCSS 7.0.
tensive episodes during HD session. The first step was software (J. Hintz, Neww, Kaysville, UT, USA).
to control BP by adjustment of “dry weight.” When this
failed, antihypertensive drug therapy was initiated [6, 7].
RESULTSPatients received as a first line drug an ACE inhibitor
(ACE-i), perindopril (4 to 8 mg every 48 h), or a dihydro- Comparisons of responders (N 68) and nonrespond-
ers (N  70) are shown on Tables 1 and 2. Responderspyridine (DHP) calcium antagonist, nitrendipine (10 to
20 mg/day). When BP control was still not achieved, a were younger (P 0.05), were on HD for a shorter time
(P 0.01), had less frequent history of CVD (P 0.001),beta-blocker, atenolol (25 to 50 mg/day), was added.
Finally, when necessary, the three drugs were used in and lower tobacco consumption (P  0.001). Ninety-
nine patients were treated with antihypertensive drugs.combination. To correct anemia, erythropoietin (EPO)
was prescribed at a dose necessary to maintain predial- Thirty-six responders (53%), and 13 nonresponders
(18%) received perindopril alone or in combination (Pysis hemoglobin between 10 to 11 g/dL.
0.001), 33 responders (49%) and 22 nonresponders
Analyses (31%) received atenolol (P  0.05), and 38 responders
(56%) and 38 nonresponders (54%) received nitrendip-According to the response of aortic PWV to BP de-
crease, the patients were divided into responders—those ine. Responders were prescribed in average 1.6 1 drugs
against 1  1.0 in nonresponders (P  0.001). For thepatients with aortic PWV decrease0.35 m/s (the regres-
sion to the mean of aortic PWV is 0.28  0.09 m/s) [10], maintenance of target hemoglobin the responders re-
ceived 70 41 U/Kg/wk of EPO in comparison with 89and nonresponders—aortic PWV insensitive to decreased
BP. All data are expressed as mean  SD. D’Agostino 47 U/Kg/wk in nonrespoders (P 0.05). Hemodynamics
and blood chemistry at baseline and end of follow-upOmnibus test was used to assess the distribution. Contin-
uous variables were compared using Student t test or are shown in Table 2. While BP decreased significantly
in both groups, SBP and PP remained significantly higherWilcoxon rank sum tests as appropriate. MANOVA was
used for multiple group comparisons of normally distrib- in nonresponders (P 0.001). Changes of LV mass index
were significantly associated with those of aortic PWVuted variables. Differences in frequency were tested by
chi-square analysis. Sex (0  male; 1  female), prior (Fig. 1), and a significant reduction of LV hypertrophy
was observed in responders. Blood chemistry did notCVD (0  no; 1  yes), diabetes (0  no; 1  yes),
perindopril (0  no; 1  yes), nitrendipine (0  no; 1  differ, with the exception of the CRP, which was higher
London et al: Inflammation and cardiovascular therapyS-90
Table 2. Hemodynamics and biochemistry in responders and nonresponders
Responders (N  68) Nonresponders (N  70)
Parameters Baseline (1) Follow-up (2) Baseline (3) Follow-up (4)
Systolic BP mm Hg 17225 13824c 16635 15630b,h
Diastolic BP mm Hg 9415 7713c 8516f 80.014b
Mean BP mm Hg 11917 10115c 11120e 10518a
Pulse pressure mm Hg 7718 6120c 8025 7625h
Heart rate bpm 7511 6914b 7513 7111a
Stroke index mL/m2 5913 5213c 6112 6119h
Cardiac index L/min/m2 4.401.12 3.611.37c 4.561.25 4.321.37h
TPR dyne · s · cm5 m2 2333717 2434901 2077651d 2152762
Aortic PWV m/s 11.502.37 9.591.98c 10.763.03 12.483.75c,h
% LV shortening 36.66.8 35.16.2 35.15.6 33.26.7g
E/A ratio 0.910.31 0.980.30a 0.820.39 0.850.38g
LV mass index g/m2 17848 14443c 16842 17653h
LV mean wall thickness mm 10.81.6 101.8b 9.61.5 10.41.6g
LV diastolic diameter mm 566.8 52.56.4c 56.55.9 56.16.3h
Body weight kg 63.114.0 63.614 61.513 59.711.9g
Serum albumin g/L 41.02.8 40.82.9 39.73.1e 39.32.8g
C-reactive protein mg/L 7.78.5 6.45.3 14.916f 13.813h
Hemoglobin g/dL 8.81.7 10.91.5c 8.51.8 10.21.3c,g
Serum phosphates mmol/L 1.950.45 1.890.43 1.890.41 1.870.42
Serum calcium mmol/L 2.360.12 2.380.14 2.420.12 2.450.15
Parathormone pg/mL 297274 274248 265218 253288
Total cholesterol mmol/L 5.11.1 5.01.1 5.41.2 5.21.2
HDL cholesterol mmol/L 1.050.27 1.050.32 1.090.28 1.070.29
Triglycerides mmol/L 1.751.00 1.650.60 1.650.18 1.630.18
1 vs 2, 3 vs 4: aP  0.05; bP  0.01; cP  0.001
1 vs 3: dP  0.05; eP  0.01; fP  0.001
2 vs 4: gP  0.05; hP  0.01; fP  0.001
(P  0.01). In the overall population, the changes of
aortic PWV were correlated with the CRP levels (P 
0.0001), and a significant positive correlation was ob-
served between aortic PWV and the CRP (Fig. 2) at the
end of follow-up. A significant correlation was observed
between changes in LV mass index and the CRP levels
(Fig. 3). In the entire population the weekly dose of
EPO necessary to maintain the target hemoglobin was
positively correlated with the CRP (Fig. 4). Variables
associated with the regression/nonregression of the aor-
tic PWVare shown in Table 4. Besides the changes in BP,
the factors retained were the CRP (factor of resistance
to treatment, [OR 1.88; 95% CI 1.20–2.94]), and the
prescription of perindopril (factor of responsivness, [OR
0.18; 95% CI 0.07–0.47]). The variation of PTH levels
were marginally significant, while variables as age, gender,Fig. 1. Scatterplots showing the correlations between the changes of
aortic PWV and that of the left ventricular mass index in hemodialysis vintage, baseline PWV, diabetes, cholesterol, changes in
patients. hemoglobin, use of atenolol or nitrendipine were re-
moved from the model by backward variable selection as
nonsignificant. Finally, in a logistic regression the factors
associated with the regression of LVH were decreased(and the serum albumin lower) in nonresponders (P 
0.001). In a multiple regression analysis, the CRP was aortic PWV, increased hemoglobin level, and prescription
positively associated with age (P  0.0001), prescription of the ACE-i (OR 0.42; 95% CI 0.19–0.95) (Table 5).
of nitrendipine (P  0.01), and triglycerides (P  0.05),
while a negative association was observed with the pre-
COMMENTSscription of perindopril (P  0.01) (Table 3). The CRP
Increased aortic PWV and LVH are independent pre-of patients treated with perindopril was 7.35  9 mg/L
in comparison with 11.7  10 in those not receiving it dictors of all-cause and cardiovascular mortality in the
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Table 3. Multivariate analysis of factors associated with serum CRP
Variable P value Incremental sequential r 2 Cumulative sequential r 2 Partial r
Age years 0.0001 0.2447 0.2447 0.5420
ACE-i no  0; yes  1 0.0027 0.0781 0.3228 0.2795
DHP no  0; yes  1 0.0056 0.0609 0.3837 0.2492
Triglycerides mmol/L 0.0401 0.0192 0.4029 0.1853
Gender 0  male; 1  female 0.0621 0.0170 0.4199 0.1695
Abbreviations are: ACE-i, perindopril; DHP, nitrendipine; CRP, C-reactive protein.
aAdjusted for the other parameters
br 2  0.4199; c F ratio  17.51; dP  0.0001
Fig. 2. Scatterplot showing the correlation between the serum CRP
and the aortic pulse wave velocity measured at the end of follow-up.
Fig. 4. Scatterplot showing the correlation between the serum CRP
and the weekly dose of erythropietin necessary to maintain the pre-
dialysis hemoglobin level between 10 and 11 g/dL.
Table 4. Logistic regression report: Variables related to  aortic
pulse wave velocity
Regression Standard
Variable coefficient error 	2, 
  0 P level
Intercept 0.069 0.503 0.02 0.8905
MBP mm Hg 0.053 0.014 14.89 0.0001
ACE-i (1, yes; 0, no) 1.722 0.488 12.43 0.0004
CRP Ln mg/L 0.632 0.228 7.68 0.0055
PTH pg/mL 0.016 0.009 3.42 0.0645
Fig. 3. Scatterplot showing the correlation between the serum CRP Abbreviations are: MBP, mean arterial pressure; ACE-i, perindopril; CRP,
and changes of the left ventricular mass index in hemodialysis patients. C-reactive protein; PTH, parathyroid hormone. P  0.00001 for differences in
variables. 	2  51.31; 0  negative; 1  positive.
general population [11] and ESRD patients [4, 6, 12].
Decrease of aortic stiffness in response to antihyperten- Table 5. Logistic regression report: Variables related to  left
ventricular mass indexsive drugs is associated with the regression of LVH and
the improvement of the survival, but is observed in less Regression Standard
Variable coefficient error 	2, 
  0 P levelthan 50% of uremic patients [6, 7]. In nonresponders,
the persistance of arterial stiffening contributes to alter- Intercept 1.038 0.318 10.68 0.0011
PWV m/s 0.370 0.010 14.76 0.0001ations in myocardial perfusion [13, 14], and of an abnor-
ACE-i yes, no 0.856 0.416 4.43 0.0387mally high PP, which is an independent determinant of Hgb g/dL 0.454 0.146 9.74 0.0018
CV and all-cause mortality of HD patients [15, 16]. The Abbreviations are: PWV, pulse wave velocity; ACE-i, perindopril; Hgb, hemo-
globin. P  0.00001 compared to variables; r 2  0.2404; 	2  46.84.regression of aortic stiffening and LVH in HD patients
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is influenced by two factors: (1) resistance to treatment of aortic stiffness to therapeutic interventions suggests
that, in ESRD patients, the chronic low-grade inflamma-is associated with chronic and moderate increase of the
serum CRP; (2) favorable response is associated with tion is associated with progressive uremic arteriopathy
and persistant pressure overload, contributing to non-the prescription of the ACE-i (Tables 4 and 5). The aortic
PWV, as well as changes of aortic PWV and changes of regression of LVH. The persistance of LVH is also favored
by lower hemoglobin and the influence of inflammationLV mass, were significantly correlated with the serum
CRP (Figs. 2 and 3). The nonregression of LVH in non- on EPO resistance [33], as shown in Fig. 4. Finally, the
use of ACE-i seems the drug of choice in ESRD patients,responders could also have been related to lesser correc-
tion of anemia, due to relative resistance to EPO in the since ACE-inhibition seems to exert a favorable and
independent effect on cardiovascular alterations.presence of higher CRP levels (Fig. 4).
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